Alosetron hydrochloride

Base Information

• Chemical Name: Alosetron hydrochloride
• CAS No.: 122852-69-1
• Molecular Formula: C17H19ClN4O
• Molecular Weight: 330.81
• Hs Code.: 2933790002
• European Community (EC) Number: 802-450-0
• UNII: 2F5R1A46YW
• DSSTox Substance ID: DTXSID8044208
• Wikidata: Q27124209
• NCI Thesaurus Code: C47386
• RXCUI: 85247
• ChEMBL ID: CHEMBL1200885
• Mol file: 122852-69-1.mol

Synonyms:2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride;alosetron;alosetron hydrochloride;alosetron monohydrochloride;GR 68755;GR68755;Lotronex

Chemical Property of Alosetron hydrochloride

Chemical Property:

• Appearance/Colour: Off-white powder
• Vapor Pressure: 1.1E-16mmHg at 25°C
• Melting Point: 288-291 °C
• Boiling Point: 648.1 °C at 760 mmHg
• Flash Point: 345.8 °C
• PSA: 53.92000
• Density: 1.34 g/cm³
• LogP: 3.14820
• Storage Temp.: Refrigerator
• Solubility.: H2O: ≥5mg/mL at warmed
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 2
• Exact Mass: 330.1247389
• Heavy Atom Count: 23
• Complexity: 442

Purity/Quality:

99% ^*data from raw suppliers

Alosetron Hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T,Xi
• Hazard Codes: T,Xi
• Statements: 25-36-52/53
• Safety Statements: 26-45

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C.Cl
• Recent EU Clinical Trials: A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects
• Description: Lotronex (alosetron) was developed for the treatment of severe irritable bowel syndrome (IBS), and was approved for use by the US Food and Drug Administration (FDA) in 2000. Although Lotronex had a relatively high improvement rate in patients taking the drug for IBS, it was voluntarily pulled from the market by GlaxoWellcome that same year due to reports of severe adverse side effects, some resulting in death. In 2002, Lotronex was reapproved in a supplemental New Drug Application for use under more restrictive conditions. Now with a risk management program to be consulted prior to administration of the drug, Lotronex is designated to be prescribed only when its medical benefits outweigh the risks of toxic effects; women with severe diarrhea-predominant IBS are now the focal point of prescriptions for Lotronex.
• Uses: Alosetron hydrochloride is used in treatment of irritable bowel syndrome Lotronex is used for severe diarrhea-predominant IBS in women. There are other potential uses, as animal models have shown at least some evidence for the ability of Lotronex to mitigate the effects of psychosis, anxiety, cognitive impairment, emesis, and drug withdrawal. These possibilities have not been verified in humans, however.
• Therapeutic Function: Antidiarrheal